Default company panoramic image
Logo

Photolitec, LLC

Photolitec (PL) is in the advanced stages of developing new photosensitizing compounds used to identify cancer through medical imaging.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Buffalo, NY, USA
  • Currency USD
  • Founded January 2010
  • Employees 9
  • Website photolitec.org

Company Summary

PL is developing cancer imaging & therapeutic agents for use in tumor detection, monitoring tumor response, assessing disease & image-guided therapy. The compounds that PL is working to commercialize create promising new oncological treatment opportunities for patients. Products are currently in the advanced development stage & customers will include imaging companies, hospitals, health care centers & cancer patients worldwide.

Team

  • Default avatar
    Ravindra K. Pandey, Ph.D.

    In 1990 Dr. Pandey joined the Photodynamic Therapy (PDT) Center at Roswell Park Cancer Institute where he is currently associated as Distinguished Professor and Director of Pharmaceutical Chemistry, Dept. of Cell Stress Biology. He also has an appointment as Professor with the Institute of Lasers, Photonics and Biophotonics, SUNY at Buffalo. Recent research has been focused on developing compounds for tumor imaging and/or PDT.

  • Default avatar
    Scott Friedman, Esq.

    Mr. Friedman is a co-founder and board member of Photolitec, LLC, as well as a Managing Partner at Lippes Mathias Wexler Frideman LLP. As a partner in the firm's business and financial transactions group, Mr. Friedman concentrates his practice on general business matters, with particular emphasis on venture capital financing transactions and on representing family-owned and closely-held businesses as well as professional partnerships.

  • Default avatar
    Sundeep Dugar, Ph.D.

    Dr. Dugar is President and CEO of Sphaera Pharma and serves as Chief Advisor for Photolitec. He has extensive experience in the pharmaceutical industry with a deep understanding of the drug discovery and development process. He is also well acquainted with the US IND submission process and clinical development (Phase I, Phase II and Phase III clinical trials).

Advisors

  • Default avatar
    Scott Friedman, Lippes Mathias Wexler Friedman LLP
    Lawyer
    Unconfirmed
    Default avatar
    Mark S. Kane, CPA, The Kane Firm
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Local Angel Investors
    Unconfirmed
    Default avatar
    RPCI Technology Funds
    Unconfirmed
    Default avatar
    Zhejiang Hisun Pharmaceutical Co., Ltd.
    Unconfirmed